Click Here to return To Results

 

Long-term Treatment of Acromegaly With Pegvisomant, a Growth Hormone Receptor Antagonist Lancet 358:1754-1759,1743, van der Lely,A.J.,et al, 2001 See this aricle in Pubmed Article Abstract Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalizes insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvi somant in 160 patients with acromegaly treated for an average of 425 days.

Related Tags

(click to filter results - removes previous filter) acromegaly growth hormone antagonist liver function enzymes neoplasm,pituitary neoplasm,pituitary,treatment of pegvisomant pituitary,adenoma treatment of neurologic disorder

Click Here to return To Results